EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 179 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.16 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $2,437,000 | +445.2% | 40,560 | +412.6% | 0.02% | +325.0% |
Q3 2019 | $447,000 | -79.2% | 7,912 | -79.5% | 0.00% | -77.8% |
Q2 2019 | $2,144,000 | -24.9% | 38,509 | -31.9% | 0.02% | -21.7% |
Q1 2019 | $2,855,000 | +289.5% | 56,533 | +210.6% | 0.02% | +283.3% |
Q4 2018 | $733,000 | -77.0% | 18,204 | -60.5% | 0.01% | -62.5% |
Q3 2018 | $3,192,000 | +0.4% | 46,049 | +9.6% | 0.02% | -5.9% |
Q2 2018 | $3,179,000 | +80.1% | 42,015 | +25.4% | 0.02% | +70.0% |
Q1 2018 | $1,765,000 | +183.3% | 33,500 | +186.3% | 0.01% | +233.3% |
Q4 2017 | $623,000 | -19.7% | 11,700 | -10.0% | 0.00% | -25.0% |
Q3 2017 | $776,000 | +238.9% | 13,000 | +348.3% | 0.00% | +300.0% |
Q2 2017 | $229,000 | +308.9% | 2,900 | +314.3% | 0.00% | – |
Q4 2016 | $56,000 | -82.0% | 700 | -84.2% | 0.00% | -100.0% |
Q3 2016 | $311,000 | +740.5% | 4,441 | +361.6% | 0.00% | – |
Q2 2016 | $37,000 | +23.3% | 962 | +140.5% | 0.00% | – |
Q3 2015 | $30,000 | +275.0% | 400 | +300.0% | 0.00% | – |
Q2 2015 | $8,000 | – | 100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Hudson Executive Capital LP | 1,323,794 | $79,534,000 | 3.54% |
Park West Asset Management LLC | 1,171,880 | $70,406,000 | 2.96% |
Matarin Capital Management, LLC | 170,008 | $10,214,000 | 0.98% |
Smith, Graham & Co., Investment Advisors, LP | 140,014 | $8,412,000 | 0.82% |
Capital Impact Advisors, LLC | 33,725 | $2,026,000 | 0.71% |
U S GLOBAL INVESTORS INC | 18,800 | $1,130,000 | 0.51% |
CHARTWELL INVESTMENT PARTNERS, LLC | 187,989 | $11,294,000 | 0.37% |
Stanley-Laman Group, Ltd. | 24,000 | $1,442,000 | 0.34% |
GLOBEFLEX CAPITAL L P | 18,751 | $1,127,000 | 0.21% |
Foundry Partners, LLC | 70,357 | $4,227,000 | 0.16% |